RCT Glargine vs NPH for Treatment of DM in Pregnancy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT06619301

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06619301
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06619301. Randomized; no masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2026-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RCT Glargine vs NPH for Treatment of DM in Pregnancy
Condition
Diabetes Mellitus in Pregnancy
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Gestational Diabetes Mellitus, Class A2
Intervention (Drug)
Insulin glargine
Intervention (Drug)
insulin NPH
Lead sponsor
Loyola University (class: other)

Record details

Record id
cardio:ct-nct06619301
Content hash
9bf5b69f3ab843c0cec8cfd86f22a047bebcff6f1722841932d26b3a5cfbda1e